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Summary
Human epididymis protein 4 (HE4) is a tumor marker approved by authority  organizations in clinical chemistry for 
the detection and monitoring recurrence of ovarian cancer. Before the assay becomes part of standard laboratory practice, 
every laboratory has to confi rm the analytical performance of the assay, declared by its manufacturers. The verifi cation of 
the analytical performance of the electrochemiluminescent assay was performed on 2 analytical platforms produced by the 
same manufacturer. Within-run (reapeatability) and within-laboratory precision were determined in accordance with the 
CLSI EP15 protocol on both analyzers. The linearity study was determined in accordance with the CLSI EP6 protocol. The 
Roche HE4 assays showed excellent within-run and within-laboratory precision (CV< 4%). Within-run precision at 2 con-
centration levels is the same on both analyzers (2.1% CV and 1.2% CV).  Within-laboratory precision was CV3.3 %, and 2.8% 
on Elecsys, respectively, 2.8% and 3.4 % on Cobas e411. The HE4 assay on Elecsys showed good linearity (r2=0,99), within 
the range of 53 to 982 pmol/L. Completely automated analytical systems for determining HE4 in serum, Elecsys and 
 Cobase411 that were verifi ed in this research have shown remarkable analytical characteristics and they meet all the ana-
lytical goals necessary for their introduction to laboratory practice. 
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JEDNA METODA – 2 ANALITIČKA SUSTAVA. 
ANALITIČKE ZNAČAJKE ELEKTROKEMILUMINISCENTNE METODE ZA ODREĐIVANJE HE4 U SERUMU
Sažetak
 Humani epididimis protein 4 (HE4) je tumorski biljeg za otkrivanje i praćenje bolesnica s karcinomom jajnika prepo-
ručen od međunarodnih organizacija i autoriteta za kliničku kemiju. Prije uvođenja testa u standardni laboratorijski rad, 
svaki laboratorij mora potvrditi analitičke karakteristike testa navedene od strane proizvođača. Verifi kacija analitičkih zna-
čajki elektrokemiluminiscentne metode za određivanje HE4 u serumu provedena je na 2 analitička sustava istog proizvođa-
ča. Preciznost u seriji (ponovljivost) i unutar laboratorijska preciznost na oba analitička sustava provedene su prema CLSI 
smjernicama, protokl EP15. Linearnost je ispitana prema CLSI smjernicama, protokol EP6. Test HE4 proizvođača Roche 
Diagnostics GmbH pokazao je izvrsnu preciznost u seriji i unutar laboratorijsku preciznost (CV < 4%). Preciznost u seriji na 
2 koncentracijske razine bila je jednaka na oba analizatora (CV2,1% i 1,2%). Unutarlaboratorijska preciznost imala je na 
Elecsys analizatoru CV3,3 %, i 2,8 %, a na Cobas e411 2,8% i 3,4 % . Test HE4 pokazao je izvrsnu linernost (r2=0,99 ) u raspo-
nu vrijednosti od 53 do 982 pmol/L na Elecsys analizatoru. Potpuno automatizirani analitički sustavi za određivanje HE4 u 
serumu ,Elecsys i Cobase411 pokazali su izvrsne analitičke karakteristike i zadovoljavaju sve analitičke zahtjeve za uvođenje 
u svakodnevni laboratorijski rad.
KLJUČNE RIJEČI: HE4, analitičke značajke testa, verifi kacija, preciznost, linearnost
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INTRODUCTION
There is a long distance between discovering 
a tumor marker molecule and its introduction to 
clinical practice. Along that road, a tumor marker 
has to meet some strict requirements of analytical 
and clinical acceptability. A lot of eﬀ ort has been 
put into tumor markers, so as to diagnose malig-
nant tumors on time, to provide adequate care for 
patients suﬀ ering from tumor, as well as to detect 
cancer recurrence. As a result, today we have a 
growing number of tumor markers. However, 
some of them have shown questionable clinical 
applicability in diﬀ erent scientifi c publications 
over a period of time. In order to put a tumor 
marker to medical practice and prove its clinical 
usability, it has to pass the following steps in the 
cancer biomarker validation, listed below (1):
1.  Sample collection and processing-evalua-
tion of preanalytical factors
2. Analytical validation of biomarker assays
3. Clinical validation of biomarker tests
4. Demonstration of clinical value
5. Regulatory approval
6. Postmarketing evaluation
The analytical validation confi rms that this 
method for determining a tumor marker has been 
accurate, precise, specifi c, robust, and stable over 
time (1-5). For quantitative methods, linearity 
with the sample dilution, parallelism, recovery 
following the analyte addition and functional sen-
sitivity need additionally to be tested. A diagnos-
tic company should give the results of every ana-
lytical validation of a tumor marker to its end user 
– a clinical laboratory. The laboratory needs to 
confi rm the manufacturer’s test performances in 
its own work conditions and surroundings before 
the introduction of the marker to everyday prac-
tice. The Clinical and Laboratory Standard Insti-
tute (CLSI) has issued a number of guidelines in 
order to ensure that the validation process remains 
synchronised everywhere in the world.
Moreover, due to the guidelines set by the 
CLSI, the diagnostic company has to validate ev-
ery method for determining tumor markers, while 
the end user – the clinical laboratory – has to veri-
fy that same method, i.e. to test if the given meth-
od in the laboratory surroundings also meets the 
specifi cations obtained by manufacturer’s valida-
tion. The analytical verifi cation performed by the 
clinical laboratory does not have to contain all the 
elements of the analytical validation performed by 
the assay manufacturer. The following parameters 






After analytical verifi cation has been con-
ducted, the clinical laboratory has to assess if the 
method meets the requirements set in advance, so 
as to make a decision whether or not it can be put 
to routine medical practice. The acceptance crite-
ria are defi ned in scientifi c literature (Ricos et al. 
for the majority of biochemical parameters and 
some tumor markers)(6), by renowned institu-
tions, assay manufacturers or external quality as-
sessment (EQA) organizers. For example, accord-
ing to the National Academy of Clinical Biochem-
istry, clinically used serum-based immunoassays 
should have interassay CV of 10% and within-as-
say variability of 5% at clinical decision concentra-
tions (7).
More than 20 years have passed from the dis-
covery of HE4 to its introduction to clinical prac-
tice. HE4 was fi rst identifi ed and described by 
Kirchhoﬀ  et al. in 1991, as a transcript exclusively 
expressed in distal epididymis (8). In 1999, Schum-
mer and his colleagues demonstrated that the HE4 
gene was primarily overexpressed in patients with 
ovarian carcinomas (9). In 2003, Hellström et al. 
performed the fi rst measurement of HE4 in the se-
rum of patients with ovarian carcinoma (10). Fi-
nally, the human epididymis protein 4 was ap-
proved as a tumor biomarker by the Food and 
Drug Administration (FDA) for monitoring recur-
rence of ovarian cancer in 2009.
In 2014, a group of medical biochemistry spe-
cialists and gynaecologists launched an initiative 
to perform analytical verifi cation of the H4 tumor 
marker fi rst on Elecsys and then on the Cobase411 
analyser at the Department of Medical Biochemis-
try in Oncology. The analytical verifi cation was 
performed prior to clinical/diagnostic validation 
(diagnostic sensitivity, diagnostic specifi city, posi-
tive and negative predictive values), so HE4 was 
introduced to the routine procedure of treating 
patients suﬀ ering from ovarian cancer in the Uni-
versity Hospital for Tumors at the University Hos-
pital Center Sestre milosrdnice. 
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MATERIALS AND METHODS
Study design
The evaluation of the analytical performance 
of electrochemiluminiscent assay was conducted 
from December 2014 to July 2015 on 2 platforms of 
the same manufacturer: Elecsys and Cobas e411 
(Roche Diagnostics GmbH, Germany). Within-run 
and within-laboratory precision were determined 
according to the CLSI EP15 protocol on both ana-
lyzers (11), using one assay reagent lot. Further-
more, linearity testing was determined according 
to CLSI EP6 (12). 
Before the evaluation began, the HE4 assay 
(Roche Diagnostics GmbH, Germany, catalogue 
number: 05950929 190, lot number: 184436) was 
calibrated on Elecsys® and Cobas e411, using HE4 
CalSet (Roche Diagnostics GmbH, Germany, cata-
logue number: 05950945 190, lot number: 179364). 
The method has been standardized against the 
HE4 EIA method from Fujirebio Diagnostics, Inc. 
The success of calibration was verifi ed using 2 lev-
els of PreciControl HE4 (Roche Diagnostics 
GmbH, Germany, catalogue number: 05950953 
190, lot number: 180300). After reconstitution in 1 
mL of deionised water, the liquid quality control 
material was dissolved in smaller volumes and 
kept frozen at -20°C for 5 days. The quality control 
material listed above was used in the evaluation 
process of within-run and within-laboratory pre-
cision. The patient samples used in the linearity 
study were collected in Vacuett e® 5 mL Z Serum 
Sep Clot Activator tubes (Greiner Bio-One GmbH, 
Austria, catalogue number: 456071). After being 
left at room temperature for 30 minutes, the sam-
ples were centrifuged (Rotofi x 32A, Hett ichZentri-
fugen, Germany) at 3500 rpm for 10 minutes. If the 
samples were not used on the same day, the se-
rum was separated from the separation gel into 
secondary tubes and frozen at -20°C.
Test principle
The electrochemiluminescenceimunoassay 
(ECLIA) is intended to be used on Elecsys and Co-
bas e411 immunoassay analyzers. The electro-
chemiluminescent (ECL) reaction is a process in 
which highly reactive species are generated from 
a stable precursor at the surface of an electrode. 
This highly reactive species react with another, 
producing light. 
The HE4 assay is based on preferences of a 
sandwich electrochemiluminescence imumunoas-
say. In the fi rst step, the patient’s sample is com-
bined with a reagent containing a biotinylated 
monoclonal HE4 specifi c antibody and a monoclo-
nal HE4 specifi c antibody, labelled with a ruthe-
nium complex. During the 9-minute incubation, 
the antibodies capture the HE4 present in the sam-
ple to form a sandwich complex. After adding 
streptavidin –coated paramagnetic microparticle-
in the second step, during another 9-minute incu-
bation, the biotinylated antibody att aches to the 
streptavidin-coated surface of the microparticles. 
The reaction mixture is transported into the mea-
suring cell where the microparticles are magneti-
cally captured on the surface of electrode. The un-
bound reagent and sample are washed away by 
ProCell. The application of voltage to the electrode 
then induces chemiluminescent emission, which 
is measured by a photomultiplier. The amount of 
the chemiluminescent signal produced is directly 
proportional to the amount of HE4 in the sample. 
The results are calculated using a calibration curve 
which is analyzer-specifi cally generated by 
2-point calibration and a master curve provided 
via the reagent barcode.
Repeatability (within-run precision)
Repeatability is a quantitative value indicat-
ing the disagreement among a set of replicate 
measurements when all the measurements are 
made under identical conditions (or within a sin-
gle run of a procedure)(11). Repeatability (within-
run precision) was assessed according to CLSI 
EP15 over 5 days in the triplicate measurement of 
2 levels of the quality control material. The mean, 
the standard deviation (SD) and the coeﬃ  cient of 
variation (CV,%) were calculated from these data. 
Within-laboratory precision
Within-laboratory precision is a quantitative 
value indicating the disagreement among repli-
cate measurements over a longer time when all 
known, major sources of measurement error with-
in the laboratory (except for major maintenance, 
recalibration, or reagent lot changes) are account-
ed for. Within-laboratory precision refl ects the ac-
cumulation of various error sources, including re-
peatability (11).
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Within-laboratory precision was assessed in 
accordance with CLSI EP15 over 5 days in the trip-
licate measurement of 2 levels of the quality con-
trol material. The mean, SD and CV were calcu-
lated from these data (12). 
Linearity
A quantitative analytical method is linear 
when there exists a mathematically verifi ed 
straightline relationship between the observed 
values and the true concentrations or activities of 
the analyte (13). The linearity study was assessed 
in accordance with the CLSI EP6 procedures, to 
verify the linear measuring interval of a measure-
ment for a measuring system. The laboratory staﬀ  
collected native serum samples in order to fi nd ex-
tremely high and low concentrations of HE4. 
Three dilutions were prepared by mixing the high 
concentration sample and low concentration sam-
ple in the following ratio: 1:3, 1:1 and 3:1. Each di-
lution and high and low concentration samples 
were analyzed in duplicate. The observed values 
were plott ed against the expected values.
Statistical analysis
All the statistical analysis were performed 
using Microsoft Excel 2007. The mean, SD and CV 
were calculated from the data obtained from the 
within-run precision and within-laboratory preci-
sion studies. The equation and R-squared value 
were obtained for the linearity study.
RESULTS
Repeatability (within-run precision)
Within-run precision, expressed as CV, for 
the quality control material at the HE4 concentra-
tion of 46.9 pmol/L was 2.1% on both, Elecsys and 
eCobas analyzers. For the quality control material 
at the HE4 concentration of 352 pmol/L within-
run CV was also the same (1.2%CV) on both ana-
lyzers (Table 1).
Table 1.
WITHIN-RUN PRECISION AND WITHIN-LABORATORY PRECISION ON THE ELECSYS 
AND ECOBAS ANALYZERS IN ACCORDANCE WITH CLSI EP15. ANALYTICAL GOALS 
FROM MANUFACTURER AND DERIVED FROM BIOLOGICAL VARIABILITY - BRAGA ET AL.
Within-run precision (CV) Within-laboratory precision (CV)
PreciControl HE4 Elecsys eCobas Elecsys eCobas
L1 – 46,9 pmol/L 2.1 % 2.1 % 3.3 % 2.8 %
L2 – 352,0 pmol/L 1.2 % 1.2 % 2.8 % 3.4 %
Manufacturer precision:
L1 – 45,7 pmol/L 1.4 % 4.2 %
L2 – 345,0 pmol/L 1.4 % 3.4 %
Braga et al. analytical goals for precision (14)
optimal desirable minimum
HE4 PreM 3.0 % 6.0 % 9.1 %
HE4 PostM 1.6 % 3.2 % 4.6 %
Table 2
LINEARITY DATA OF EXPECTED AND OBSERVED CONCENTRATION ON ELECSYS.
Sample Ratio 1st replicate 2nd replicate Expected concentration
Observed 
concentration
H (ID 0042) 1 983.70 980.60 982.15 982.15
H:L 3:1 747.10 739.50 749.85 743.30
H:L 1:1 524.60 519.30 517.56 521.95
H:L 1:3 273.40 282.00 285.26 277.70
L (ID 0004) 1 52.81 53.11 52.96 52.96
H – sample with high HE4 concentration; L – sample with low HE4 concentration
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Within-run precision reached desirable ana-
lytical goals derived from biological variability (14).
Within-laboratory precision 
Within-laboratory CV on the Elecsys analyz-
er for PreciControl HE4 Level1 was higher (3.3%) 
than within-laboratory CV on the eCobas analyzer 
(2.8%). On the contrary, within-laboratory CV on 
Elecsys analyzer for PreciControl HE4 Level2 was 
lower (2.8%) than within-laboratory CV on the 
eCobas analyzer (3.4%).
Within-laboratory CV fully met the manufac-
turer criteria for within-laboratory precision (Ta-
ble 1.)
Linearity
The linearity data for the Elecsys analyzer are 
shown in Table 2 and Figure 1. The manufacturer 
has declared that the linearity range of HE4 assay 
is15 – 15000 pmol/L. In accordance with CLSI EP6, 
linearity was demonstrated throughout the mea-
suring range, from53 to 982 pmol/L, with R2 of 
0,9998.
DISCUSSION
This research has demonstrated some of the 
HE4 immunoassay analytical performances. Al-
though the verifi cation process is one of the as-
pects of the ISO 15189:2012 standard in the pro-
cess of medical laboratory accreditation, its true 
value becomes clear when a new test is being in-
troduced into a laboratory. We had such a situa-
tion when we were the fi rst laboratory in Croatia 
to introduce a completely new parameter, HE4, to 
routine laboratory practice. 
When introducing assay into laboratory 
practice, it is necessary to confi rm the technical 
performances received from the manufacturer, as 
well as to compare them with relevant fi ndings in 
scientifi c literature. Taking into consideration the 
fact that HE4, as a new test, has been available to 
the laboratories for only a few years, it is not such 
a strange fact that the biological variability and 
analytical requirements were defi ned only by Bra-
ga F. et al. in 2014 (14). They conducted their re-
search on an analyzer produced by the same man-
ufacturer and they also used the same method, 
but on diﬀ erent analytical system. The precision 
study of the HE4 method on the Roche analyzers 
obtained in this research cannot be compared to 
any other similar research studies in scientifi c lit-
erature, since there are almost no other works 
dealing with that topic. In study of the referent in-
tervals for HE4 and CA125 for Asian population, 
Park et al. described the precision of the HE4 as-
say, but conducted it on the Abbott  Architect 
i2000SR analyzer (Abbott  Laboratories, Abbott 
Park, IL), through testing based on a completely 
diﬀ erent method: chemiluminescentmicroparticle 
immunoassay (15). 
Within-run precision in this research is the 
same on both analyzers for normal (2.1%) and 
high (1.2%) analyte concentration, which meets 
the desirable specifi cation for precision (HE4PreM 
≤6.0% ; HE4PostM ≤ 3.2%), determined by Braga 
F. et al. (14) Within-run precision is in accordance 
with the optimal specifi cation, but only for HE4P-
reM≤ 3.0%(14). Although these are two diﬀ erent 
methods, we can only state that the repeatability 
by Park et al.(15) on the Abbott  analytical system 
was 2.8% CV for low and high concentrations, in 
comparison with our 2.1 and 1.2% CV. Within-run 
precision for normal concentrationon both analyz-
ers does not meet the specifi cations set by the 
manufacturer. The reason for that might be the 
fact that the manufacturer used the CLSI EP5 pro-
tocol to test the precision: 2 runs per day in a du-
plicate, each for 21 days, which is diﬀ erent from 
our CLSI EP15: a triplicate measurement during a 
5-day period. 
Within-laboratory precision on both analyz-
ers completely meets the specifi cations set by the 
manufacturer on both concentration levels. It is 
interesting that the within-laboratory CV is lower 
on the Elecsys analyzer at a high concentration 
level (3.3% vs. 2.8%), while the within-laboratory 
Figure 1. Observed HE4 values plott ed against expected values 
in linearity study.
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CV is lower on the eCobas analyzer at a normal 
concentration level (2.8% vs. 3.4%). The total pre-
cision described in the works of Park et al. ranges 
from 2.9 to 6.5%CV, depending on the concentra-
tion level (15). 
It is diﬃ  cult to make an analogy between the 
analytical goals for precision set by Braga F. et al. 
and the results of our research, since in their re-
search they used the serum of patients that were 
divided into two groups: premenopausal women 
and postmenopausal women. In this research, in-
stead of patients’ serum we tested precision by us-
ing commercially available material - PreciControl 
HE4 that contains 2 concentration levels, which is 
in accordance with CLSI EP15.
Within-run and within-laboratory precision 
completely met the criteria set by the National 
Academy of Clinical Biochemistry: the interassay 
CV of 10% and within-assay variability of 5% (7), 
so we can conclude that the HE4 immunoassay, 
set on both tested analytical systems, is an assay of 
distinguished precision. 
The test linearity in this research was also 
outstanding. We did not cover the whole linearity 
interval declared by the manufacturer. The linear-
ity at lower levels of HE4 concentration in serum 
was not tested, because it does not have any clini-
cal signifi cance. We used patient’s serum for lin-
earity testing, so it is diﬃ  cult to fi nd human serum 
with a concentration level on the upmost bor-
derline of the declared linearity (1500 pmol/L). An 
extremely pathologically high concentration level 
of 982 pmol/L was best we could reach to test lin-
earity. 
Verifi cation requests for quantitative method 
is also method comparison and accuracy. The ac-
curacy study was not conducted, because the cer-
tifi ed referential material (CRM) was not available 
at the time when the verifi cation was done, when 
the assay still had not been introduced to labora-
tory practice. When it comes to the relevance of 
HE4, it is enough to say that until a year ago none 
of the leading European institutions for the exter-
nal quality assessment of medical-biochemistry 
laboratories had HE4 as one of their standard pa-
rameters. The RfB DGKL external quality assess-
ment organizer from Germany still have not of-
fered HE4 in their panel of tumor markers, while 
Labquality (Finland) introduced it only last year. 
The accuracy study comparison with the al-
ready existent referential system was also impos-
sible, since HE4 determining was yet to be intro-
duced to laboratory practice. It was not possible to 
make a comparison with other laboratories in 
Croatia, because we were the fi rst laboratory in 
our country to introduce HE4 to our laboratory 
practice. The comparison results between Elecsys 
and Cobas e411 would certainly be interesting, 
but also inapplicable, because one analytical sys-
tem was replaced by another one in laboratories 
throughout the world (RocheDiagnostics GmbH 
recalled the Elecsys analyzers, having it replaced 
by the eCobas systems). 
The introduction of in-serum HE4 to routine 
laboratory practice and the use of that tumor 
marker for treating patients suﬀ ering from ovari-
an cancer (16) inevitably lead to a question wheth-
er or not the results of determining HE4 in serum 
from diﬀ erent laboratories are comparable (17). 
Will changing the laboratory in which the tumor 
marker is determined cause bias in concentration 
that is not a sign of recovery or a recurring dis-
ease, but simply an indicator that the analytical 
method has been changed?
This is why specialist in laboratory medicine 
has to write a information about the manufactur-
er, the method and the analyzer on which the tu-
mor marker was determined below the results of a 
tumor marker. Medical specialists are completely 
aware that diﬀ erent immunochemical methods 
are mutually incomparable, which is why they al-
ways send the same patients to the same labora-
tory. That way they ensure that the bias in the test 
results is caused only by a patient’s changed con-
dition and not by variations of the method, the 
analyzer manufacturer or the reagent. Also, spe-
cialist in laboratory medicine should to inform 
doctors who diagnose, operate and monitor pa-
tients about a properly performed process of ana-
lytical verifi cation and, eventually, about its re-
sults. It is one of the ways to build trust in the doc-
tor – biochemist relationship. The fi nal decision on 
the applicability and use of a tumor marker is al-
ways made by the doctor anyway. As it seems 
now, the future of HE4 in the University Hospital 
for Tumors is unquestionable.
CONCLUSION
The completely automated analytical sys-
tems for determining HE4 in serum –Elecsys and 
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Cobas e411 – verifi ed in this research have shown 
some remarkable analytical characteristics and 
they meet all the analytical goals for sett ing the as-
say to laboratory practice. We can say for sure that 
bias in the concentration of HE4 in serum during 
the treatments of patients suﬀ ering from gynaeco-
logical cancer does not lie in the analytical meth-
od, but in the real change of the concentration of 
tumor markers in the bodies of the patients. Avail-
ability of a precise, linear and robust immunoas-
say for determining HE4 is the main precondition 
for an early diagnosis and proper treatment of pa-
tients suﬀ ering from ovarian cancer in Croatia. 
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